Obesity is a complex disease characterized by excessive fat accumulation which is caused
by genetic, environmental and other factors. In recent years, there has been an increase in …

The incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent
insulinotropic polypeptide (GIP) are released from enteroendocrine cells in response to the …

Introduction Obesity is frequently a comorbidity of type 2 diabetes. Even modest weight loss
can significantly improve glucose homeostasis and lessen cardiometabolic risk factors in …

GLP-1, a peptide hormone secreted from the gut, stimulating insulin and suppressing
glucagon secretion was identified as a parent compound for novel treatments of diabetes …

Aims To compare efficacy and safety of glucagon‐like peptide‐1 receptor agonists (GLP‐
1RAs) in people with type 2 diabetes. Materials and methods We electronically searched, up …

Type 2 diabetes mellitus (T2DM) is a global epidemic that poses a major challenge to health-
care systems. Improving metabolic control to approach normal glycaemia (where practical) …

In healthy humans, the incretin glucagon-like peptide 1 (GLP-1) is secreted after eating and
lowers glucose concentrations by augmenting insulin secretion and suppressing glucagon …

In light of the worldwide epidemic of obesity, and in recognition of hypertension as a major
factor in the cardiovascular morbidity and mortality associated with obesity, The Obesity …

Aims To review the evolution and advancement of GLP‐1 receptor agonist (GLP‐1RA)
therapy, through the lens of randomised controlled trials, from differentiating characteristics …

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of injective anti-diabetic
drugs that improve glycemic control and many other atherosclerosis-related parameters in …